Search Results - "Mau‐Sørensen, Morten"

HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis by Egebjerg, Kristian, Harwood, Cecilie Dupont, Woller, Nina Claire, Kristensen, Claus Andrup, Mau-Sørensen, Morten

“…HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of HER2 directed therapy have been reported in small studies. However, reliable…”
Get full text

Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data by Egebjerg, Kristian, Andersen, Tobias Sørup, Bæksgaard, Lene, Garbyal, Rajendra, Siemsen, Mette, Achiam, Michael, Mau-Sørensen, Paul Morten

“…Perioperative 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) is recommended in resectable esophagogastric adenocarcinoma based on randomised trials…”
Get full text

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy by Borch, Annie, Bjerregaard, Anne-Mette, Araujo Barbosa de Lima, Vinicius, Østrup, Olga, Yde, Christina Westmose, Eklund, Aron Charles, Mau-Sørensen, Morten, Barra, Carolina, Svane, Inge Marie, Nielsen, Finn Cilius, Funt, Samuel A, Lassen, Ulrik, Hadrup, Sine Reker

“…Immune checkpoint inhibition for the treatment of cancer has provided a breakthrough in oncology, and several new checkpoint inhibition pathways are currently…”
Get full text

Enhanced detection of circulating tumor DNA by fragment size analysis by Mouliere, Florent, Chandrananda, Dineika, Piskorz, Anna M, Moore, Elizabeth K, Morris, James, Ahlborn, Lise Barlebo, Mair, Richard, Goranova, Teodora, Marass, Francesco, Heider, Katrin, Wan, Jonathan C M, Supernat, Anna, Hudecova, Irena, Gounaris, Ioannis, Ros, Susana, Jimenez-Linan, Mercedes, Garcia-Corbacho, Javier, Patel, Keval, Østrup, Olga, Murphy, Suzanne, Eldridge, Matthew D, Gale, Davina, Stewart, Grant D, Burge, Johanna, Cooper, Wendy N, van der Heijden, Michiel S, Massie, Charles E, Watts, Colin, Corrie, Pippa, Pacey, Simon, Brindle, Kevin M, Baird, Richard D, Mau-Sørensen, Morten, Parkinson, Christine A, Smith, Christopher G, Brenton, James D, Rosenfeld, Nitzan

“…Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties…”
Get more information

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours by van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.

“…Background This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of…”
Get full text

Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer by Eefsen, Rikke Løvendahl, Larsen, Jim S., Klarskov, Louise L., Altaf, Rahim, Høgdall, Estrid, Ingeholm, Peter, Lykke, Jakob, Nielsen, Dorte L., Pfeiffer, Per, Poulsen, Laurids Ø., Qvortrup, Camilla, Schou, Jakob V., Mau‐Sørensen, Morten, Østerlind, Kell, Jensen, Benny V.

“…Therapy with immune checkpoint inhibitors (ICI) is effective in patients with metastatic mismatch‐repair deficient (dMMR) colorectal cancer (CRC); however,…”
Get full text

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer by Chen, Ying, Camacho, Sandra Catalina, Silvers, Thomas R, Razak, Albiruni R A, Gabrail, Nashat Y, Gerecitano, John F, Kalir, Eva, Pereira, Elena, Evans, Brad R, Ramus, Susan J, Huang, Fei, Priedigkeit, Nolan, Rodriguez, Estefania, Donovan, Michael, Khan, Faisal, Kalir, Tamara, Sebra, Robert, Uzilov, Andrew, Chen, Rong, Sinha, Rileen, Halpert, Richard, Billaud, Jean-Noel, Shacham, Sharon, McCauley, Dilara, Landesman, Yosef, Rashal, Tami, Kauffman, Michael, Mirza, Mansoor R, Mau-Sørensen, Morten, Dottino, Peter, Martignetti, John A

“…The high fatality-to-case ratio of ovarian cancer is directly related to platinum resistance. Exportin-1 (XPO1) is a nuclear exporter that mediates nuclear…”
Get full text

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies by Dirix, Luc, MD, PhD, Swaisland, Helen, Verheul, Henk M.W., MD, PhD, Rottey, Sylvie, MD, PhD, Leunen, Karin, MD, Jerusalem, Guy, MD, PhD, Rolfo, Christian, MD, PhD, Nielsen, Dorte, MD, DMSc, Molife, L. Rhoda, BMedSci, BM BS, MRCP, MD, MSc, Kristeleit, Rebecca, BSc, MRCP, PhD, Vos-Geelen, Judith de, MD, PhD, Mau-Sørensen, Morten, MD, PhD, Soetekouw, Patricia, MD, van Herpen, Carla, MD, PhD, Fielding, Anitra, MBChB, So, Karen, MBBS, MRCS, MD, Bannister, Wendy, Plummer, Ruth, MD, D.Phil, FRCP

“…Abstract Purpose The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA -mutated…”
Get full text

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) by Chen, Christine, Garzon, Ramiro, Gutierrez, Martin, Jacoby, Meagan A., Brown, Peter, Flinn, Ian, Stone, Richard M., Savoie, Mary Lynn, Baz, Rachid, Gabrail, Nashat Y., Wang, Michael, Martin, Peter, Siegel, David, Mau-Sørensen, Morten, Andreef, Michael, Marshall, Tracey, Saint-Martin, Jean-Richard, Carlson, Robert, Shacham, Sharon, Kauffman, Michael, Kuruvilla, John

“…Background: The nuclear export protein XPO1 is overexpressed in all types of hematological malignancies. The SINE selinexor (KPT-330) is a novel,…”
Get full text

Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis by Egebjerg, Kristian, Garbyal, Rajendra Singh, Hasselby, Jane Preuss, Baeksgaard, Lene, Mau-Sørensen, Morten

“…[Display omitted] •HER2 targeted therapy is currently not used in squamous cell esophageal cancer.•Literature was reviewed to assess rate of HER2…”
Get full text

Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials by Tuxen, Ida Viller, Rohrberg, Kristoffer Staal, Oestrup, Olga, Ahlborn, Lise Barlebo, Schmidt, Ane Yde, Spanggaard, Iben, Hasselby, Jane P, Santoni-Rugiu, Eric, Yde, Christina Westmose, Mau-Sørensen, Morten, Nielsen, Finn Cilius, Lassen, Ulrik

“…We evaluated the clinical benefit of tumor molecular profiling to select treatment in the phase I setting. Patients with advanced solid cancers and exhausted…”
Get full text

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3 by Mau-Sørensen, Morten, Dittrich, Christian, Dienstmann, Rodrigo, Lassen, Ulrik, Büchler, Wilfried, Martinius, Holger, Tabernero, Josep

“…Purpose The aim of the study was to evaluate the safety and determine the maximum tolerated dose (MTD) of intravenous catumaxomab, a trifunctional bispecific…”
Get full text

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma by Lassman, Andrew B, Wen, Patrick Y, van den Bent, Martin J, Plotkin, Scott R, Walenkamp, Annemiek M E, Green, Adam L, Li, Kai, Walker, Christopher J, Chang, Hua, Tamir, Sharon, Henegar, Leah, Shen, Yao, Alvarez, Mariano J, Califano, Andrea, Landesman, Yosef, Kauffman, Michael G, Shacham, Sharon, Mau-Sørensen, Morten

“…Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various solid and hematologic tumors. We assessed intratumoral penetration,…”
Get full text

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors by Steeghs, Neeltje, Gomez-Roca, Carlos, Rohrberg, Kristoffer S, Mau-Sørensen, Morten, Robbrecht, Debbie, Tabernero, Josep, Ahmed, Samreen, Rodriguez-Ruiz, Maria E, Ardeshir, Caroline, Schmid, Daniela, Sleiman, Nassim, Watson, Carl, Piper-Lepoutre, Hanna, Dejardin, David, Evers, Stefan, Boetsch, Christophe, Charo, Jehad, Teichgräber, Volker, Melero, Ignacio

“…Simlukafusp alfa (FAP-IL2v), a tumor-targeted immunocytokine, comprising an interleukin-2 variant moiety with abolished CD25 binding fused to human…”
Get full text

Perioperative exercise training for patients with gastrointestinal cancer undergoing surgery: A systematic review and meta-analysis by Thomsen, Simon Nørskov, Mørup, Stine Truel, Mau-Sørensen, Morten, Sillesen, Martin, Lahart, Ian, Christensen, Jesper Frank

“…Exercise training is emerging as a supportive treatment strategy in surgical oncology, but its effects remain uncertain in patients with gastrointestinal…”
Get full text

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer by Smyth, Lillian M, Piha-Paul, Sarina A, Won, Helen H, Schram, Alison M, Saura, Cristina, Loi, Sherene, Lu, Janice, Shapiro, Geoffrey I, Juric, Dejan, Mayer, Ingrid A, Arteaga, Carlos L, de la Fuente, Macarena I, Brufksy, Adam M, Spanggaard, Iben, Mau-Sørensen, Morten, Arnedos, Monica, Moreno, Victor, Boni, Valentina, Sohn, Joohyuk, Schwartzberg, Lee S, Gonzàlez-Farré, Xavier, Cervantes, Andrés, Bidard, François-Clement, Gorelick, Alexander N, Lanman, Richard B, Nagy, Rebecca J, Ulaner, Gary A, Chandarlapaty, Sarat, Jhaveri, Komal, Gavrila, Elena I, Zimel, Catherine, Selcuklu, S Duygu, Melcer, Myra, Samoila, Aliaksandra, Cai, Yanyan, Scaltriti, Maurizio, Mann, Grace, Xu, Feng, Eli, Lisa D, Dujka, Melanie, Lalani, Alshad S, Bryce, Richard, Baselga, José, Taylor, Barry S, Solit, David B, Meric-Bernstam, Funda, Hyman, David M

“…mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the…”
Get more information

Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET‐dysregulated solid tumours by Chen, Xinhui, Isambert, Nicolas, López‐López, Rafael, Giovannini, Monica, Pognan, Nathalie, Kapoor, Shruti, Quinlan, Michelle, You, Benoit, Cui, Xiaoming, Rahmanzadeh, Gholamreza, Mau‐Sorensen, Morten

“…Background Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time‐dependent manner. In this study, we…”
Get full text

Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review by Grunnet, Mie, Mau-Sørensen, Morten, Brünner, Nils

“…Abstract Objective. The value of Tissue Inhibitor of MetalloProteinase-1 (TIMP-1) as a biomarker in patients with gastric cancer (GC) is widely debated. The…”
Get full text

Dose reduced preoperative chemotherapy in older patients with resectable gastroesophageal cancer: A real-world data study by Skjoldbirk, Josephine, Egebjerg, Kristian, Qvortrup, Camilla, Lund, Cecilia M., Bæksgaard, Lene, Achiam, Michael Patrick, Mau-Sørensen, Morten

“…Older patients with gastroesophageal (GE) cancer are at increased risk of low treatment tolerability and poor outcome. Dose reduced chemotherapy has been shown…”
Get full text

Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers by Høgdall, Dan, O'Rourke, Colm J, Dehlendorff, Christian, Larsen, Ole F, Jensen, Lars H, Johansen, Astrid Z, Dang, Hien, Factor, Valentina M, Grunnet, Mie, Mau-Sørensen, Morten, Oliveira, Douglas V N P, Linnemann, Dorte, Boisen, Mogens K, Wang, Xin W, Johansen, Julia S, Andersen, Jesper B

“…Biliary tract cancer (BTC) is a heterogeneous group of rare gastrointestinal malignancies with dismal prognosis often associated with inflammation. We assessed…”
Get full text